Healthcare / BiotechnologyNasdaqCM
$2.24
-0.02 (-0.88%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-14.8M · quality 68.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
22/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$143M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-143.6%
↓Gross Margin
N/A
•Debt/Equity
0.03
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2011–2025 · 14 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.92x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-30.1M · FCF $-27.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||||
| Net Income | $-30.1M | $-30.1M | $-21.7M | $-29.3M | $-9.4M | $-38.3M | $-9.1M | $-8.0M | $11.1M | $8.1M | $8.9M | $-4.3M | $6.4M | $-8.3M | $-2.4M | $-1.3M |
| EBITDA | $-29.4M | $-29.4M | $-17.4M | $-29.1M | $-9.0M | — | — | — | — | — | — | — | — | — | — | — |
| EPS | -0.63 | -0.63 | -1.21 | -2.47 | -0.77 | -2800.00 | -1522.50 | 5530.00 | 9485.00 | 12950.00 | 14525.00 | 1925.00 | 0.00 | — | — | — |
| Balance Sheet | ||||||||||||||||
| Debt/Equity | 0.03 | 0.03 | 0.01 | -1.50 | 0.01 | — | — | — | 0.00 | 0.00 | 0.14 | — | — | — | — | — |
| Current Ratio | 1.15 | 1.15 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||||||
| Free Cash Flow | $-27.7M | $-27.7M | $-14.8M | $-12.0M | $-7.5M | — | — | — | — | — | — | — | — | — | — | — |
| Returns | ||||||||||||||||
| ROE | -143.6% | -143.6% | -148.6% | 1880.8% | -76.1% | -362.0% | -3470.0% | -409.0% | 204.9% | 122.9% | 182.5% | 529.3% | -705.6% | 1013.6% | 180.8% | 152.0% |
| Valuation | ||||||||||||||||
| P/B | 5.13 | 5.13 | 5.74 | — | 270.86 | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | ||||||||||||||||
| EPS Growth | 47.9% | 47.9% | 51.0% | -221.1% | — | -83.9% | -127.5% | -41.7% | -26.8% | -10.8% | 654.5% | — | — | — | — | — |
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-26.8%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.21 → -0.63
Residual
-26.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.